Surprisingly (unbelievably?) impressive RCT evaluating the Blys/APRIL inhibitor "telitacicept" for patients with SLE (mixed SLE and SLE-LN). Very curious to see where the FDA goes with this one. Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2414719
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Evidence Based Rheumatology Podcast
E135: IL17 and a GLP1?
E134: Brepocitinib in Dermatomyositis (VALOR)
E133: Obinutuzumab for SLE (ALLEGORY)
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
Get summaries like this every morning.
Free AI-powered recaps of The Evidence Based Rheumatology Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.